Scientific Background and Reference Sources
Abbosh, C., Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R., Le Quesne, J., Moore, D. A., Veeriah, S., Rosenthal, R., Marafioti, T., Kirkizlar, E., Watkins, T. B. K., McGranahan, N., Ward, S., Martinson, L., Riley, J., Fraioli, F., Al Bakir, M., . . . Swanton, C. (2017). Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 545(7655), 446-451. https://doi.org/10.1038/nature22364
Adaptive_Biotechnologies. (2024a). ClonoSEQ MRD Monitoring. Retrieved 7/10/20 https://www.clonoseq.com/for-clinicians/clonoseq-assay/
Al-Sawaf, O., Zhang, C., Robrecht, S., Wilson, C., Tandon, M., Ching, T., Fink, A. M., Ritgen, M., Tausch, E., Kreuzer, K.-A., Schary, W., Wendtner, C. M., Eichhorst, B., Stilgenbauer, S., Jiang, Y., Hallek, M., & Fischer, K. (2020). Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial. Blood, 136(Supplement 1), 22-23. https://doi.org/10.1182/blood-2020-136977
Al-Sawaf, O., Zhang, C., Tandon, M., Sinha, A., Fink, A. M., Robrecht, S., Samoylova, O., Liberati, A. M., Pinilla-Ibarz, J., Opat, S., Sivcheva, L., Le Dû, K., Fogliatto, L. M., Niemann, C. U., Weinkove, R., Robinson, S., Kipps, T. J., Tausch, E., Schary, W., Fischer, K. (2020). Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol, 21(9), 1188-1200. https://doi.org/10.1016/s1470-2045(20)30443-5
Arber, D. A., Borowitz, M. J., Cessna, M., Etzell, J., Foucar, K., Hasserjian, R. P., Rizzo, J. D., Theil, K., Wang, S. A., Smith, A. T., Rumble, R. B., Thomas, N. E., Vardiman, J. W. (2017). Initial Diagnostic Workup of Acute Leukemia: Guideline from the College of American Pathologists and the American Society of Hematology. Arch Pathol Lab Med, 141(10), 1342-1393. https://doi.org/10.5858/arpa.2016-0504-CP
Bai, Y., Orfao, A., & Chim, C. S. (2018). Molecular detection of minimal residual disease in multiple myeloma. Br J Haematol, 181(1), 11-26. https://doi.org/10.1111/bjh.15075
Berger, B. M., Hanna, G. J., Posner, M. R., Genden, E. M., Lautersztain, J., Naber, S. P., Del Vecchio Fitz, C., & Kuperwasser, C. (2022). Detection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among Patients Treated for HPV-Driven Oropharyngeal Carcinoma. Clinical Cancer Research, 28(19), 4292-4301. https://doi.org/10.1158/1078-0432.ccr-22-0562
Brüggemann, M., Raff, T., Flohr, T., Gökbuget, N., Nakao, M., Droese, J., Lüschen, S., Pott, C., Ritgen, M., Scheuring, U., Horst, H. A., Thiel, E., Hoelzer, D., Bartram, C. R., & Kneba, M. (2006). Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood, 107(3), 1116-1123. https://doi.org/10.1182/blood-2005-07-2708
Caers, J., Garderet, L., Kortum, K. M., O'Dwyer, M. E., van de Donk, N., Binder, M., Dold, S. M., Gay, F., Corre, J., Beguin, Y., Ludwig, H., Larocca, A., Driessen, C., Dimopoulos, M. A., Boccadoro, M., Gramatzki, M., Zweegman, S., Einsele, H., Cavo, M. Engelhardt, M. (2018). European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica, 103(11), 1772-1784. https://doi.org/10.3324/haematol.2018.189159
Carlson, J. J., Eckert, B., & Zimmerman, M. (2019). Cost-effectiveness of next-generation sequencing minimal residual disease testing during maintenance treatment for multiple myeloma. Journal of Clinical Oncology, 37(15_suppl), e19529-e19529. https://doi.org/10.1200/JCO.2019.37.15_suppl.e19529
Christensen, E., Birkenkamp-Demtroder, K., Sethi, H., Shchegrova, S., Salari, R., Nordentoft, I., Wu, H. T., Knudsen, M., Lamy, P., Lindskrog, S. V., Taber, A., Balcioglu, M., Vang, S., Assaf, Z., Sharma, S., Tin, A. S., Srinivasan, R., Hafez, D., Reinert, T., . . . Dyrskjot, L. (2019). Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. J Clin Oncol, 37(18), 1547-1557. https://doi.org/10.1200/JCO.18.02052
Coombes, R. C., Page, K., Salari, R., Hastings, R. K., Armstrong, A., Ahmed, S., Ali, S., Cleator, S., Kenny, L., Stebbing, J., Rutherford, M., Sethi, H., Boydell, A., Swenerton, R., Fernandez-Garcia, D., Gleason, K. L. T., Goddard, K., Guttery, D. S., Assaf, Z. J., . . . Shaw, J. A. (2019). Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clin Cancer Res, 25(14), 4255-4263. https://doi.org/10.1158/1078-0432.CCR-18-3663
de Haas, V., Ismaila, N., Advani, A., Arber, D. A., Dabney, R. S., Patel-Donnelly, D., Kitlas, E., Pieters, R., Pui, C.-H., Sweet, K., & Zhang, L. (2018). Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline. Journal of Clinical Oncology, 37(3), 239-253. https://doi.org/10.1200/JCO.18.01468
Del Giudice, I., Raponi, S., Della Starza, I., De Propris, M. S., Cavalli, M., De Novi, L. A.,Cappelli, L. V., Ilari, C., Cafforio, L., Guarini, A., & Foà, R. (2019). Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal? Front Oncol, 9, 689. https://doi.org/10.3389/fonc.2019.00689
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hajek, R., Schjesvold, F., Cavo, M., Goldschmidt, H., Facon, T., Einsele, H., Boccadoro, M., San-Miguel, J., Sonneveld, P., Mey, U., guidelines@ehaweb.org, E. H. A. G. C. E. a., & clinicalguidelines@esmo.org, E. G. C. E. a. (2021). Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger). Ann Oncol, 32(3), 309-322. https://doi.org/10.1016/j.annonc.2020.11.014
Eichhorst, B., Ghia, P., & on behalf of the, E. H. A. G. C. (2021). EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia. HemaSphere, 5(1). https://journals.lww.com/hemasphere/Fulltext/2021/01000/EHA_Endorsement_of_ESMO_Clinical_Practice.14.aspx
Eichhorst, B., Robak, T., Montserrat, E., Ghia, P., Niemann, C. U., Kater, A. P., Gregor, M., Cymbalista, F., Buske, C., Hillmen, P., Hallek, M., Mey, U., & clinicalguidelines@esmo.org, E. G. C. E. a. (2021). Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 32(1), 23-33. https://doi.org/10.1016/j.annonc.2020.09.019
Eroglu, Z., Krinshpun, S., Kalashnikova, E., Sudhaman, S., Ozturk Topcu, T., Nichols, M., Martin, J., Bui, K. M., Palsuledesai, C. C., Malhotra, M., Olshan, P., Markowitz, J., Khushalani, N. I., Tarhini, A. A., Messina, J. L., & Aleshin, A. (2023). Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Cancer, 129(11), 1723-1734. https://doi.org/10.1002/cncr.34716
Fakih, M., Sandhu, J., Wang, C., Kim, J., Chen, Y. J., Lai, L., Melstrom, K., & Kaiser, A. (2022). Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer. JAMA Netw Open, 5(3), e221093. https://doi.org/10.1001/jamanetworkopen.2022.1093
Faulkner, L. G., Howells, L. M., Pepper, C., Shaw, J. A., & Thomas, A. L. (2023). The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis. British journal of cancer, 128(2), 297-309.
FDA. (2018, 09/28/2020). EVALUATION OF AUTOMATIC CLASS II DESIGNATION FOR clonoSEQ® ASSAY DECISION SUMMARY. Retrieved 7/13/2020 from https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN170080.pdf
FDA. (2020). 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY. Retrieved 8/2/2021 from https://www.accessdata.fda.gov/cdrh_docs/reviews/K200009.pdf
Friend, B. D., Bailey-Olson, M., Melton, A., Shimano, K. A., Kharbanda, S., Higham, C., Winestone, L. E., Huang, J., Stieglitz, E., & Dvorak, C. C. (2020). The impact of total body irradiation-based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer, 67(2), e28079. https://doi.org/10.1002/pbc.28079
Goicoechea, I., Puig, N., Cedena, M. T., Burgos, L., Cordon, L., Vidriales, M. B., Flores-Montero, J., Gutierrez, N. C., Calasanz, M. J., Ramos, M. M., Lara-Astiaso, D., Vilas-Zornoza, A., Alignani, D., Rodriguez, I., Sarvide, S., Alameda, D., Garces, J. J., Rodriguez, S., Fresquet, V.Paiva, B. (2021). Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood, 137(1), 49-60. https://doi.org/10.1182/blood.2020006731
Gunning, A., Kumar, S., Williams, C. K., Berger, B. M., Naber, S. P., Gupta, P. B., Del Vecchio Fitz, C., & Kuperwasser, C. (2023). Analytical Validation of NavDx, a cfDNA-Based Fragmentomic Profiling Assay for HPV-Driven Cancers. Diagnostics, 13(4), 725. https://www.mdpi.com/2075-4418/13/4/725
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H., Hillmen, P., Keating, M., Montserrat, E., Chiorazzi, N., Stilgenbauer, S., Rai, K. R., Byrd, J. C., Eichhorst, B., O'Brien, S., Robak, T., Seymour, J. F., & Kipps, T. J. (2018). iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood, 131(25), 2745-2760. http://doi.org/10.1182/blood-2017-09-806398
Hay, K. A., Gauthier, J., Hirayama, A. V., Voutsinas, J. M., Wu, Q., Li, D., Gooley, T. A., Cherian, S., Chen, X., Pender, B. S., Hawkins, R. M., Vakil, A., Steinmetz, R. N., Schoch, G., Chapuis, A. G., Till, B. G., Kiem, H. P., Ramos, J. D., Shadman, M.,Turtle, C. J. (2019). Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood, 133(15), 1652-1663. https://doi.org/10.1182/blood-2018-11-883710
Herrera, A. F., Kim, H. T., Kong, K. A., Faham, M., Sun, H., Sohani, A. R., Alyea, E. P., Carlton, V. E., Chen, Y. B., Cutler, C. S., Ho, V. T., Koreth, J., Kotwaliwale, C., Nikiforow, S., Ritz, J., Rodig, S. J., Soiffer, R. J., Antin, J. H., & Armand, P. (2016). Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Br J Haematol, 175(5), 841-850. http://doi.org/10.1111/bjh.14311
Heuser, M., Ofran, Y., Boissel, N., Brunet Mauri, S., Craddock, C., Janssen, J., Wierzbowska, A., & Buske, C. (2020). Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. https://doi.org/10.1016/j.annonc.2020.02.018
Hoelzer, D., Bassan, R., Dombret, H., Fielding, A., Ribera, J. M., & Buske, C. (2016). Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 27(suppl 5), v69-v82. https://doi.org/10.1093/annonc/mdw025
Hofste, L. S. M., Geerlings, M. J., Kamping, E. J., Kouwenhoven, N. D. H., von Rhein, D., Jansen, E. A. M., Garms, L. M., Nagtegaal, I. D., van der Post, R. S., de Wilt, J. H. W., Klarenbeek, B. R., & Ligtenberg, M. J. L. (2023). Clinical Validity of Tumor-Informed Circulating Tumor DNA Analysis in Patients Undergoing Surgery of Colorectal Metastases. Dis Colon Rectum, 66(6), 796-804. https://doi.org/10.1097/DCR.0000000000002443
Horton, T. M., & Steuber, C. P. (2023, December 19). Risk group stratification and prognosis for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents. https://www.uptodate.com/contents/risk-group-stratification-and-prognosis-for-acute-lymphoblastic-leukemia-lymphoblastic-lymphoma-in-children-and-adolescents
Jacome, A. A., & Johnson, B. (2023). Minimal Residual Disease in Colorectal Cancer: Are We Finding the Needle in a Haystack? Cells, 12(7). https://doi.org/10.3390/cells12071068
Kater, A. P., Seymour, J. F., Hillmen, P., Eichhorst, B., Langerak, A. W., Owen, C., Verdugo, M., Wu, J., Punnoose, E. A., Jiang, Y., Wang, J., Boyer, M., Humphrey, K., Mobasher, M., & Kipps, T. J. (2019). Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol, 37(4), 269-277. https://doi.org/10.1200/jco.18.01580
Khaddour, K., Zhou, A., Butt, O. H., Budde, G., Malashevich, A. K., & Ansstas, G. (2022). Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios. Front Oncol, 12, 978996. https://doi.org/10.3389/fonc.2022.978996
Kim, H. Y., Yoo, I. Y., Lim, D. J., Kim, H. J., Kim, S. H., Yoon, S. E., Kim, S. J., Cho, D., & Kim, K. (2022). Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma. Ann Lab Med, 42(5), 558-565. https://doi.org/10.3343/alm.2022.42.5.558
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Blade, J., Mateos, M. V., Dimopoulos, M., Kastritis, E., Boccadoro, M., Orlowski, R., Goldschmidt, H., Spencer, A., Hou, J., Chng, W. J., Usmani, S. Z., Avet-Loiseau, H. (2016). International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol, 17(8), e328-e346. https://doi.org/10.1016/s1470-2045(16)30206-6
Lee, S., Kim, D. W., Cho, B., Kim, Y. J., Kim, Y. L., Hwang, J. Y., Park, Y. H., Shin, H. J., Park, C. Y., Min, W. S., Kim, H. K., & Kim, C. C. (2003). Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol, 120(1), 145-153. https://doi.org/10.1046/j.1365-2141.2003.03988.x
Loupakis, F., Sharma, S., Derouazi, M., Murgioni, S., Biason, P., Rizzato, M. D., Rasola, C., Renner, D., Shchegrova, S., Koyen Malashevich, A., Malhotra, M., Sethi, H., Zimmermann, B. G., Aleshin, A., Moshkevich, S., Billings, P. R., Sedgwick, J. D., Schirripa, M., Munari, G., . . . Fassan, M. (2021). Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases. JCO Precis Oncol, 5. https://doi.org/10.1200/PO.21.00101
Luskin, M. R., Murakami, M. A., Manalis, S. R., & Weinstock, D. M. (2018). Targeting minimal residual disease: a path to cure? Nat Rev Cancer, 18(4), 255-263. https://doi.org/10.1038/nrc.2017.125
Madzo, J., Zuna, J., Muzíková, K., Kalinová, M., Krejcí, O., Hrusák, O., Otova, B., Stary, J., & Trka, J. (2003). Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study. Cancer, 97(1), 105-113. https://doi.org/10.1002/cncr.11043
Medina, A., Puig, N., Flores-Montero, J., Jimenez, C., Sarasquete, M. E., Garcia-Alvarez, M., Prieto-Conde, I., Chillon, C., Alcoceba, M., Gutierrez, N. C., Oriol, A., Rosinol, L., Blade, J., Gironella, M., Hernandez, M. T., Gonzalez-Calle, V., Cedena, M. T., Paiva, B., San-Miguel, J. F.,Garcia-Sanz, R. (2020). Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer J, 10(10), 108. https://doi.org/10.1038/s41408-020-00377-0
Mikhael, J., Ismaila, N., Cheung, M. C., Costello, C., Dhodapkar, M. V., Kumar, S., Lacy, M., Lipe, B., Little, R. F., Nikonova, A., Omel, J., Peswani, N., Prica, A., Raje, N., Seth, R., Vesole, D. H., Walker, I., Whitley, A., Wildes, T. M., Martin, T. (2019). Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. Journal of Clinical Oncology, 37(14), 1228-1263. https://doi/org/10.1200/JCO.18.02096
Moding, E. J., Nabet, B. Y., Alizadeh, A. A., & Diehn, M. (2021). Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. Cancer Discov, 11(12), 2968-2986. https://doi.org/10.1158/2159-8290.CD-21-0634
Natera. (2024). Signatera™ Transforming the management of cancer with personalized testing. https://www.natera.com/oncology/signatera-advanced-cancer-detection/
NCCN. (2024a, July 19, 2024). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Acute Lymphoblastic Leukemia Version 2.2024. https://www.nccn.org/professionals/physician_gls/pdf/all.pdf
NCCN. (2024b, 5/17/2024). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Acute Myeloid Leukemia Version 3.2024. https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
NCCN. (2024c, October 1, 2024). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Chronic Lymphocytic Leukemia / Small Lymphocytic Leukemia Version 1.2025. https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf
NCCN. (2024d, September 26, 2024). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Hairy Cell Leukemia Version 1.2025. https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf
NCCN. (2024e, September 17, 2024). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Multiple Myeloma Version 1.2025. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
NCCN. (2024f, August 28, 2024). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Pediatric Acute Lymphoblastic Leukemia Version 1.2025. https://www.nccn.org/professionals/physician_gls/pdf/ped_all.pdf
Nguyen Hoang, T. P., Nguyen, T. A., Tran, N. H. B., Nguyen Hoang, V. A., Thi Dao, H. T., Tran, V. U., Nguyen, Y. N., Nguyen, A. T., Nguyen Thi, C. T., Do Thi, T. T., Nguyen, D. S., Nguyen, H. N., Giang, H., & Tu, L. N. (2024). Analytical validation and clinical utilization of K-4CARE™: a comprehensive genomic profiling assay with personalized MRD detection. Front Mol Biosci, 11, 1334808. https://doi.org/10.3389/fmolb.2024.1334808
O'Sullivan, H. M., Feber, A., & Popat, S. (2023). Minimal Residual Disease Monitoring in Radically Treated Non-Small Cell Lung Cancer: Challenges and Future Directions. Onco Targets Ther, 16, 249-259. https://doi.org/10.2147/OTT.S322242
Perrot, A., Lauwers-Cances, V., Corre, J., Robillard, N., Hulin, C., Chretien, M. L., Dejoie, T., Maheo, S., Stoppa, A. M., Pegourie, B., Karlin, L., Garderet, L., Arnulf, B., Doyen, C., Meuleman, N., Royer, B., Eveillard, J. R., Benboubker, L., Dib, M., Munshi, N. (2018). Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood, 132(23), 2456-2464. https://doi.org/10.1182/blood-2018-06-858613
Rai, K. R., & Stilgenbauer, S. (2024, February 13). Evaluating response to treatment of chronic lymphocytic leukemia. https://www.uptodate.com/contents/evaluating-response-to-treatment-of-chronic-lymphocytic-leukemia
Rajkumar, S. V. (2023, September 25, 2023). Multiple myeloma: Evaluating response to treatment. https://www.uptodate.com/contents/multiple-myeloma-evaluating-response-to-treatment
Rawstron, A. C., Fazi, C., Agathangelidis, A., Villamor, N., Letestu, R., Nomdedeu, J., Palacio, C., Stehlikova, O., Kreuzer, K. A., Liptrot, S., O'Brien, D., de Tute, R. M., Marinov, I., Hauwel, M., Spacek, M., Dobber, J., Kater, A. P., Gambell, P., Soosapilla, A., Ghia, P. (2016). A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia, 30(4), 929-936. https://doi.org/10.1038/leu.2015.313
Reinert, T., Henriksen, T. V., Christensen, E., Sharma, S., Salari, R., Sethi, H., Knudsen, M., Nordentoft, I., Wu, H. T., Tin, A. S., Heilskov Rasmussen, M., Vang, S., Shchegrova, S., Frydendahl Boll Johansen, A., Srinivasan, R., Assaf, Z., Balcioglu, M., Olson, A., Dashner, S., . . . Lindbjerg Andersen, C. (2019). Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol, 5(8), 1124-1131. https://doi.org/10.1001/jamaoncol.2019.0528
Robak, T., Matutes, E., Catovsky, D., Zinzani, P. L., & Buske, C. (2015). Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 26 Suppl 5, v100-107. https://doi.org/10.1093/annonc/mdv200
Royston, D. J., Gao, Q., Nguyen, N., Maslak, P., Dogan, A., & Roshal, M. (2016). Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma. Am J Clin Pathol, 146(1), 41-49. https://doi.org/10.1093/ajcp/aqw052
Sato, S., Nakamura, Y., Oki, E., & Yoshino, T. (2023). Molecular Residual Disease-guided Adjuvant Treatment in Resected Colorectal Cancer: Focus on CIRCULATE-Japan. Clin Colorectal Cancer, 22(1), 53-58. https://doi.org/10.1016/j.clcc.2022.12.001
Schuurhuis, G. J., Heuser, M., Freeman, S., Bene, M. C., Buccisano, F., Cloos, J., Grimwade, D., Haferlach, T., Hills, R. K., Hourigan, C. S., Jorgensen, J. L., Kern, W., Lacombe, F., Maurillo, L., Preudhomme, C., van der Reijden, B. A., Thiede, C., Venditti, A., Vyas, P., Ossenkoppele, G. J. (2018). Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 131(12), 1275-1291. https://doi.org/10.1182/blood-2017-09-801498
Stock, W., & Estrov, Z. (2022a, 6/16/2022). Clinical use of measurable residual disease detection in acute lymphoblastic leukemia. https://www.uptodate.com/contents/clinical-use-of-measurable-residual-disease-detection-in-acute-lymphoblastic-leukemia
Stock, W., & Estrov, Z. (2020b, 3/7/2022). Detection of measurable residual disease in acute lymphoblastic leukemia. https://www.uptodate.com/contents/detection-of-measurable-residual-disease-in-acute-lymphoblastic-leukemia
Subhash, V. V., Huang, L., Kamili, A., Wong, M., Chen, D., Venn, N. C., Atkinson, C., Mayoh, C., Venkat, P., Tyrrell, V., Marshall, G. M., Cowley, M. J., Ekert, P. G., Norris, M. D., Haber, M., Henderson, M. J., Sutton, R., Fletcher, J. I., & Trahair, T. N. (2022). Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma. Br J Cancer, 126(3), 482-491. https://doi.org/10.1038/s41416-021-01538-z
Sullivan, B. G., Dayyani, F., & Senthil, M. (2023). ASO Author Reflections: Challenges of Circulating Tumor DNA in the Management of Gastrointestinal Peritoneal Carcinomatosis. Ann Surg Oncol, 30(1), 285-286. https://doi.org/10.1245/s10434-022-12543-8
Theunissen, P., Mejstrikova, E., Sedek, L., van der Sluijs-Gelling, A. J., Gaipa, G., Bartels, M., Novakova, M., Sonneveld, E., Buracchi, C., Bonaccorso, P., Oliveira, E., Te Marvelde, J. G., Szczepanski, T., Lhermitte, L., Hrusak, O., Lecrevisse, Q., Grigore, G. E., van der Velden, V. H. (2017). Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood, 129(3), 347-357. http://doi.org/10.1182/blood-2016-07-726307
Thompson, P. A., Srivastava, J., Peterson, C., Strati, P., Jorgensen, J. L., Hether, T., Keating, M. J., O'Brien, S. M., Ferrajoli, A., Burger, J. A., Estrov, Z., Jain, N., & Wierda, W. G. (2019). Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood, 134(22), 1951-1959. https://doi.org/10.1182/blood.2019001077
Thörn, I., Forestier, E., Botling, J., Thuresson, B., Wasslavik, C., Björklund, E., Li, A., Lindström-Eriksson, E., Malec, M., Grönlund, E., Torikka, K., Heldrup, J., Abrahamsson, J., Behrendtz, M., Söderhäll, S., Jacobsson, S., Olofsson, T., Porwit, A., Lönnerholm, G., Sundström, C. (2011). Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry. Br J Haematol, 152(6), 743-753. https://doi.org/10.1111/j.1365-2141.2010.08456.x
Tie, J., Cohen, J. D., Wang, Y., Christie, M., Simons, K., Lee, M., Wong, R., Kosmider, S., Ananda, S., McKendrick, J., Lee, B., Cho, J. H., Faragher, I., Jones, I. T., Ptak, J., Schaeffer, M. J., Silliman, N., Dobbyn, L., Li, L., . . . Gibbs, P. (2019). Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. JAMA Oncol, 5(12), 1710-1717. https://doi.org/10.1001/jamaoncol.2019.3616
Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H. L., Christie, M., Kosmider, S., Skinner, I., Wong, R., Steel, M., Tran, B., Desai, J., Jones, I., Haydon, A., Hayes, T., . . . Gibbs, P. (2016). Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med, 8(346), 346ra392. https://doi.org/10.1126/scitranslmed.aaf6219
van der Velden, V. H. J., Hochhaus, A., Cazzaniga, G., Szczepanski, T., Gabert, J., & van Dongen, J. J. M. (2003). Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia, 17(6), 1013-1034. https://doi.org/10.1038/sj.leu.2402922
Wang, Y., Li, L., Cohen, J. D., Kinde, I., Ptak, J., Popoli, M., Schaefer, J., Silliman, N., Dobbyn, L., Tie, J., Gibbs, P., Tomasetti, C., Kinzler, K. W., Papadopoulos, N., Vogelstein, B., & Olsson, L. (2019). Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. JAMA Oncol, 5(8), 1118-1123. https://doi.org/10.1001/jamaoncol.2019.0512
Wang, Z., Guo, M., Zhang, Y., Xu, S., Cheng, H., Wu, J., Zhang, W., Hu, X., Yang, J., Wang, J., &. . . Tang, G. (2019). The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation. Int J Lab Hematol, 41(5), 607-614. https://doi.org/10.1111/ijlh.13070
Wood, B., Wu, D., Crossley, B., Dai, Y., Williamson, D., Gawad, C., Borowitz, M. J., Devidas, M., Maloney, K. W., Larsen, E., Winick, N., Raetz, E., Carroll, W. L., Hunger, S. P., Loh, M. L., Robins, H., & Kirsch, I. (2018). Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood, 131(12), 1350-1359.
Zhang, S., Brazel, D., Kumar, P., Schafer, L. N., Eidenschink, B., Senthil, M., & Dayyani, F. (2021). Utility of tumor-informed circulating tumor DNA in the clinical management of gastrointestinal malignancies. J Gastrointest Oncol, 12(6), 2643-2652. https://doi.org/10.21037/jgo-21-484
Zhong, R., Gao, R., Fu, W., Li, C., Huo, Z., Gao, Y., Lu, Y., Li, F., Ge, F., Tu, H., You, Z., He, J., & Liang, W. (2023). Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis. BMC Med, 21(1), 180. https://doi.org/10.1186/s12916-023-02849-z https://doi.org/10.1182/blood-2017-09-806521
Specialty Matched Consultant Advisory Panel review- 8/2021
Medical Director review 11/2022
Medical Director review 10/2023
Medical Director review 7/2024
Medical Director review 12/2024